Caeli Nova is an exciting new venture that aims to improve human safety and performance via the application of medical science. We have developed and patented new breathing technology which successfully improves oxygenation in a number of challenging environments. By re-thinking the science behind human performance, we can successfully improve safety, and survivability in critical situations, overcoming long established limitations. Our products aim to make our environment safer and greener.
Location: United Kingdom, England, London
Employees: 11-50
Total raised: $8.63M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Armada | armada.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.01.2022 | Series A | $8.63M | - |
Mentions in press and media 2
| Date | Title | Description |
| 11.01.2022 | Caeli Nova raises CHF 8 million in Series A funding round | |
| 04.01.2022 | Caeli Nova jets off with €7.7 million to deliver its new emergency oxygen system onto passenger aircraft and beyond | Switzerland and London-based Caeli Nova has just closed its Series A funding with €7.7 million in a round spearheaded by LG Capital and led by Ornament Health. Other investors include Latécoère. Innovating at the intersection of aviation an... |